1,4-二氢-4-氧杂吡咯并[1,2- b ]哒嗪-3-羧酸和1,4-二氢-4-氧杂咪唑并[1,5 - b ]哒嗪-3-羧酸的合成代理商
摘要:
为了检查喹诺酮的两个氮杂类似物家族的抗菌潜力,分别是1,4-二氢-4-氧杂吡咯并[1,2 - b ]哒嗪-3-羧酸和1,4-二氢-4-氧杂咪唑[1, 5 - b ]哒嗪-3-羧酸,我们使用N-氨基吡咯和N-氨基咪唑衍生物作为起始结构单元和喹诺酮系列的经典途径,制备了这些家族中的一些衍生物。这些化合物没有显示出令人感兴趣的抗菌活性。
[EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012125887A1
公开(公告)日:2012-09-20
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
申请人:Incyte Corporation
公开号:US20140200227A1
公开(公告)日:2014-07-17
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
申请人:Incyte Corporation
公开号:US20140200216A1
公开(公告)日:2014-07-17
The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
In general, the instant invention comprises compounds of Formulas I and II
including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
In general, the instant invention comprises compounds of Formulas I and II
including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.